Reardon Tighe has filed 3 insider transactions across 1 company since January 2024.
Most recent transaction: a sale of 131196 shares of Janux Therapeutics, Inc. ($JANX) on June 03, 2024.
Activity breakdown: 0 open-market purchases and 2 sales.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| June 3, 2024 | Janux Therapeutics, Inc. | $JANX | Reardon Tighe | Acting Chief Financial Officer | S | Common Stock | 131196 | $54.75 | 4,148,680.0000 | 44,016,283 | 3.07% | 0.30% |
| June 3, 2024 | Janux Therapeutics, Inc. | $JANX | Reardon Tighe | Acting Chief Financial Officer | S | Common Stock | 691525 | $54.75 | 4,148,680.0000 | 44,016,283 | 14.29% | 1.57% |
| Jan. 2, 2024 | Janux Therapeutics, Inc. | $JANX | Reardon Tighe | Acting Chief Financial Officer | A | Stock Option (right to buy) | 157000 | $0.00 | 157,000.0000 | 44,016,283 | 9999.99% | 0.36% |